Anticancer Drugs Market

Anticancer Drugs Market (Drug Type: Cytotoxic Drugs, Targeted Drugs, and Hormonal Drugs; and Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

Anticancer Drugs Market Outlook 2031

  • The global industry was valued at US$ 140.2 Bn in 2022
  • It is estimated to grow at a CAGR of 9.1% from 2023 to 2031 and reach US$ 303.1 Bn by the end of 2031

Analyst Viewpoint

High efficacy of monoclonal antibodies (mAbs) and rise in demand for organic treatments are propelling the anticancer drugs market size. Monoclonal antibodies are gaining traction as a favored method for the treatment of several types of cancer.

Governments in several countries are implementing various regulatory frameworks to support the R&D of anticancer medicines, which is offering lucrative opportunities to vendors in the global anticancer drugs industry. Vendors are conducting clinical trials to evaluate various drugs for the treatment of cancer. They are also acquiring other companies and investing in cutting-edge anticancer therapeutics to expand their customer base.

Anticancer Drugs Market

Market Introduction

Cancer is a category of diseases characterized by abnormal cell formation with the potential to afflict or spread to other parts of the body. Carcinomas, sarcomas, lymphomas, and leukemia are all common types of tumors. Sarcomas begin in connective tissues such as muscle or bones. Sarcomas of the delicate tissues can begin in oily tissues. The management of cancer in patients requires the application of various treatments including hormone therapy, immunotherapy, targeted therapy, and other modalities.

Cancer is currently a leading cause of mortality worldwide, according to the World Health Organization (WHO), with 10 million annual deaths in 2020. Thus, high prevalence of cancer is fueling the anticancer drugs market value. The pharmaceutical industry is expanding rapidly, particularly in the field of anticancer medications and treatments. Rise in awareness about malignant diseases is boosting demand for anticancer drugs.

Significant costs associated with the R&D of new medicines and side effects associated with anticancer therapies are likely to limit the anticancer drugs market growth in the near future. Surge in healthcare expenditure in emerging countries and increase in investment in the R&D of new medicines are projected to offer lucrative anticancer drugs industry opportunities to vendors.

Major countries across the globe are implementing various regulatory frameworks to support the R&D of anticancer medications. In the U.S., the Food and Drug Administration has developed an educational initiative in association with the Oncology Center of Excellence (OCE) under the moniker Oncology Regulatory Expertise and Early Guidance (OREEG). It aims to aid early-stage oncology companies with anticancer drug research for quicker and more efficient development of relevant oncology drugs.

High Efficacy of Monoclonal Antibodies Bolstering Anticancer Drugs Market Development

Monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to mimic the immune system's ability to fight off cancer cells and other harmful pathogens. Innovative small molecule inhibitors for melanoma represent an innovative approach to developing treatments for this type of cancer.

Monoclonal antibodies are designed to interact with specific targets. Targeted mAbs can cause tumor cell death by a variety of mechanisms. In October 2023, The Medicines and Healthcare Products Regulatory Agency (MHRA) authorized a new indication for Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults. This monoclonal antibody treatment is beneficial for patients with certain types of advanced or recurrent endometrial cancer. Thus, approval and launch of novel monoclonal antibody treatments is projected to augment the anticancer drugs market progress in the next few years.

According to the latest anticancer drugs market analysis, monoclonal antibodies are applied in emerging immunotherapy drugs for lung cancer. Some monoclonal antibodies label cancer cells so that the immune system can better recognize and eliminate them. Rituximab, for example, attaches to a protein called CD20 on B cells and certain cancer cells, prompting the immune system to destroy them. This technique allows doctors to target tumors without harming healthy cells. It usually has fewer adverse effects than other cancer therapies and is very effective in the battle against cancer.

Rise in Demand for Organic Treatments Driving Anticancer Drugs Market Expansion

Integrative oncology research helps to determine whether complementary therapies, including herbal anticancer drugs, are safe and effective to be combined with traditional cancer treatments. For more than a half-century, natural compounds with robust chemical diversity have been widely researched for their anticancer properties. Microbes and plants from terrestrial and marine settings are the primary suppliers of these chemicals. Microorganisms are a significant source of antitumor natural compounds. Several of these products were first identified as anticancer antibiotics.

Plant alkaloids, taxoids, and podophyllotoxins are classes of compounds derived from plants that have shown significant therapeutic potential, particularly in the field of cancer treatment. Taxol (paclitaxel), for example, is a mesothelioma chemotherapy medication derived from the bark of the yew tree. Rapidly developing resistance to chemotherapeutic treatments has necessitated the development of innovative medications for cancer therapy. The high toxicity and unfavorable side effects of traditional medicines are prompting the development of organic therapeutic substances. According to a March 2020 report by the American Chemical Society and the American Society of Pharmacognosy, natural products were responsible for nearly 25% of all newly authorized anticancer medications between 1981 and 2019. Hence, R&D of organic treatments is fueling the anticancer drugs market revenue.

Regional Outlook

According to the latest anticancer drugs market forecast, North America is projected to hold largest share from 2023 to 2031. Rise in prevalence of cancer and presence of modern healthcare infrastructure are fueling the market dynamics of the region. Surge in healthcare expenditure and easy availability of pharmaceuticals is also boosting the anticancer drugs industry trajectory in North America.

Analysis of Key Players

Major players are investing in the R&D of new products to expand their product portfolio and increase their anticancer drugs market share. Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bayer AG, Merck & Co. Inc., and Celgene Corporation are key players operating in this market.

Each of these players has been profiled in the anticancer drugs market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments

  • In September 2023, Amgen reported data from a Phase Ib study of the CodeBreaK 101 clinical trial evaluating LUMAKRAS (sotorasib) along with carboplatin and pemetrexed to treat adults with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)
  • In March 2023, Pfizer acquired Seagen for US$ 43.0 Bn in a bid to invest in its cutting-edge anticancer therapeutics. The company announced plans to scale its antibody-drug conjugate products that employ antibodies to transport small molecule medications directly to a tumor location.

Anticancer Drugs Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 140.2 Bn
Market Forecast Value in 2031 US$ 303.1 Bn
Growth Rate (CAGR) 9.1%
Forecast Period 2023 to 2031
Historical Data Available for 2021
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2023
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia and CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC
  • South Africa
Market Segmentation
  • Drug Type
    • Cytotoxic Drugs
      • Alkylating Agents
      • Antimetabolites
      • Others
    • Targeted Drugs
      • Monoclonal Antibodies
      • Tyrosine Kinase Inhibitors
      • Others
    • Hormonal Drugs
  • Therapy Type
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
    • Others
  • Cancer Type
    • Lung Cancer
    • Breast Cancer
    • Leukemia
    • Colorectal Cancer
    • Others
Companies Profiled
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Merck & Co. Inc.
  • Celgene Corporation
Customization Scope Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the anticancer drugs market in 2022?

It was valued at US$ 140.2 Bn in 2022

How is the anticancer drugs business expected to grow by 2031?

It is likely to grow at a CAGR of 9.1% from 2023 to 2031

What are the key factors driving the demand for anticancer drugs?

High efficacy of monoclonal antibodies and rise in demand for organic treatments

Which was the major region in the anticancer drugs landscape in 2022?

North America held largest share in 2022

Who are the key anticancer drugs manufacturers?

Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bayer AG, Merck & Co. Inc., and Celgene Corporation

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Anticancer Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Anticancer Drugs Market Analysis and Forecast, 2023–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Anticancer Drugs Market Analysis and Forecast, by Drug Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Drug Type, 2023–2031

            6.3.1. Cytotoxic Drugs

                6.3.1.1. Alkylating Agents

                6.3.1.2. Antimetabolites

                6.3.1.3. Others

            6.3.2. Targeted Drugs

                6.3.2.1. Monoclonal Antibodies

                6.3.2.2. Tyrosine Kinase Inhibitors

                6.3.2.3. Others

            6.3.3. Hormonal Drugs

        6.4. Market Attractiveness Analysis, by Drug Type

    7. Global Anticancer Drugs Market Analysis and Forecast, by Therapy Type

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Therapy Type, 2023–2031

            7.3.1. Chemotherapy

            7.3.2. Targeted Therapy

            7.3.3. Immunotherapy

            7.3.4. Others

        7.4. Market Attractiveness Analysis, by Therapy Type

    8. Global Anticancer Drugs Market Analysis and Forecast, by Cancer Type

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Cancer Type, 2023–2031

            8.3.1. Lung Cancer

            8.3.2. Breast Cancer

            8.3.3. Leukemia

            8.3.4. Colorectal Cancer

            8.3.5. Others

        8.4. Market Attractiveness Analysis, by Therapy Type

    9. Global Anticancer Drugs Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2023–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Anticancer Drugs Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Drug Type, 2023–2031

            10.3.1. Cytotoxic Drugs

                10.3.1.1. Alkylating Agents

                10.3.1.2. Antimetabolites

                10.3.1.3. Others

            10.3.2. Targeted Drugs

                10.3.2.1. Monoclonal Antibodies

                10.3.2.2. Tyrosine Kinase Inhibitors

                10.3.2.3. Others

            10.3.3. Hormonal Drugs

        10.4. Market Value Forecast, by Therapy Type, 2023–2031

            10.4.1. Chemotherapy

            10.4.2. Targeted Therapy

            10.4.3. Immunotherapy

            10.4.4. Others

        10.5. Market Value Forecast, by Cancer Type, 2023–2031

            10.5.1. Lung Cancer

            10.5.2. Breast Cancer

            10.5.3. Leukemia

            10.5.4. Colorectal Cancer

            10.5.5. Others

        10.6. Market Value Forecast, by Country, 2023–2031

            10.6.1. U.S.

            10.6.2. Canada

        10.7. Market Attractiveness Analysis

            10.7.1. By Drug Type

            10.7.2. By Therapy Type

            10.7.3. By Cancer Type

            10.7.4. By Country

    11. Europe Anticancer Drugs Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Drug Type, 2023–2031

            11.3.1. Cytotoxic Drugs

                11.3.1.1. Alkylating Agents

                11.3.1.2. Antimetabolites

                11.3.1.3. Others

            11.3.2. Targeted Drugs

                11.3.2.1. Monoclonal Antibodies

                11.3.2.2. Tyrosine Kinase Inhibitors

                11.3.2.3. Others

            11.3.3. Hormonal Drugs

        11.4. Market Value Forecast, by Therapy Type, 2023–2031

            11.4.1. Chemotherapy

            11.4.2. Targeted Therapy

            11.4.3. Immunotherapy

            11.4.4. Others

        11.5. Market Value Forecast, by Cancer Type, 2023–2031

            11.5.1. Lung Cancer

            11.5.2. Breast Cancer

            11.5.3. Leukemia

            11.5.4. Colorectal Cancer

            11.5.5. Others

        11.6. Market Value Forecast, by Country/Sub-region, 2023–2031

            11.6.1. Germany

            11.6.2. U.K.

            11.6.3. France

            11.6.4. Italy

            11.6.5. Spain

            11.6.6. Rest of Europe

        11.7. Market Attractiveness Analysis

            11.7.1. By Drug Type

            11.7.2. By Therapy Type

            11.7.3. By Cancer Type

            11.7.4. By Country/Sub-region

    12. Asia Pacific Anticancer Drugs Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Drug Type, 2023–2031

            12.3.1. Cytotoxic Drugs

                12.3.1.1. Alkylating Agents

                12.3.1.2. Antimetabolites

                12.3.1.3. Others

            12.3.2. Targeted Drugs

                12.3.2.1. Monoclonal Antibodies

                12.3.2.2. Tyrosine Kinase Inhibitors

                12.3.2.3. Others

            12.3.3. Hormonal Drugs

        12.4. Market Value Forecast, by Therapy Type, 2023–2031

            12.4.1. Chemotherapy

            12.4.2. Targeted Therapy

            12.4.3. Immunotherapy

            12.4.4. Others

        12.5. Market Value Forecast, by Cancer Type, 2023–2031

            12.5.1. Lung Cancer

            12.5.2. Breast Cancer

            12.5.3. Leukemia

            12.5.4. Colorectal Cancer

            12.5.5. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2023–2031

            12.6.1. China

            12.6.2. Japan

            12.6.3. India

            12.6.4. Australia & New Zealand

            12.6.5. Rest of Asia Pacific

        12.7. Market Attractiveness Analysis

            12.7.1. By Drug Type

            12.7.2. By Therapy Type

            12.7.3. By Cancer Type

            12.7.4. By Country/Sub-region

    13. Latin America Anticancer Drugs Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Drug Type, 2023–2031

            13.3.1. Cytotoxic Drugs

                13.3.1.1. Alkylating Agents

                13.3.1.2. Antimetabolites

                13.3.1.3. Others

            13.3.2. Targeted Drugs

                13.3.2.1. Monoclonal Antibodies

                13.3.2.2. Tyrosine Kinase Inhibitors

                13.3.2.3. Others

            13.3.3. Hormonal Drugs

        13.4. Market Value Forecast, by Therapy Type, 2023–2031

            13.4.1. Chemotherapy

            13.4.2. Targeted Therapy

            13.4.3. Immunotherapy

            13.4.4. Others

        13.5. Market Value Forecast, by Cancer Type, 2023–2031

            13.5.1. Lung Cancer

            13.5.2. Breast Cancer

            13.5.3. Leukemia

            13.5.4. Colorectal Cancer

            13.5.5. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2023–2031

            13.6.1. Brazil

            13.6.2. Mexico

            13.6.3. Rest of Latin America

        13.7. Market Attractiveness Analysis

            13.7.1. By Drug Type

            13.7.2. By Therapy Type

            13.7.3. By Cancer Type

            13.7.4. By Country/Sub-region

    14. Middle East & Africa Anticancer Drugs Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Drug Type, 2023–2031

            14.3.1. Cytotoxic Drugs

                14.3.1.1. Alkylating Agents

                14.3.1.2. Antimetabolites

                14.3.1.3. Others

            14.3.2. Targeted Drugs

                14.3.2.1. Monoclonal Antibodies

                14.3.2.2. Tyrosine Kinase Inhibitors

                14.3.2.3. Others

            14.3.3. Hormonal Drugs

        14.4. Market Value Forecast, by Therapy Type, 2023–2031

            14.4.1. Chemotherapy

            14.4.2. Targeted Therapy

            14.4.3. Immunotherapy

            14.4.4. Others

        14.5. Market Value Forecast, by Cancer Type, 2023–2031

            14.5.1. Lung Cancer

            14.5.2. Breast Cancer

            14.5.3. Leukemia

            14.5.4. Colorectal Cancer

            14.5.5. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2023–2031

            14.6.1. GCC Countries

            14.6.2. South Africa

            14.6.3. Rest of Middle East & Africa

        14.7. Market Attractiveness Analysis

            14.7.1. By Drug Type

            14.7.2. By Therapy Type

            14.7.3. By Cancer Type

            14.7.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. F. Hoffmann-La Roche Ltd

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. Eli Lilly and Company

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. Novartis AG

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. Pfizer Inc

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. Bayer AG

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. AstraZeneca

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. Takeda Pharmaceutical Company Limited

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. Merck & Co., Inc

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

            15.3.9. CELGENE CORPORATION

                15.3.9.1. Company Overview

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Financial Overview

                15.3.9.5. Strategic Overview

            15.3.10. Amgen Inc

                15.3.10.1. Company Overview

                15.3.10.2. Product Portfolio

                15.3.10.3. SWOT Analysis

                15.3.10.4. Financial Overview

                15.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

    Table 02: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

    Table 03: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

    Table 04: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Region, 2023–2031

    Table 05: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country, 2023–2031

    Table 06: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

    Table 07: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

    Table 08: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

    Table 09: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 10: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

    Table 11: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

    Table 12: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

    Table 13: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 14: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

    Table 15: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

    Table 16: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

    Table 17: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 18: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

    Table 19: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

    Table 20: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

    Table 21: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 22: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

    Table 23: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

    Table 24: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

    List of Figures

    Figure 01: Global Anticancer Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031

    Figure 02: Global Anticancer Drugs Market Revenue (US$ Mn), by Drug Type, 2022

    Figure 03: Global Anticancer Drugs Market Value Share, by Drug Type, 2022

    Figure 04: Global Anticancer Drugs Market Revenue (US$ Mn), by Therapy Type, 2022

    Figure 05: Global Anticancer Drugs Market Value Share, by Therapy Type, 2022

    Figure 06: Global Anticancer Drugs Market Revenue (US$ Mn), by Cancer Type, 2022

    Figure 07: Global Anticancer Drugs Market Value Share, by Cancer Type, 2022

    Figure 08: Global Anticancer Drugs Market Value Share, by Region, 2022

    Figure 09: Global Anticancer Drugs Market Value (US$ Mn) Forecast, 2023–2031

    Figure 10: Global Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

    Figure 11: Global Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031

    Figure 12: Global Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

    Figure 13: Global Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031

    Figure 14: Global Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

    Figure 15: Global Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031

    Figure 16: Global Anticancer Drugs Market Value Share Analysis, by Region, 2023 and 2031

    Figure 17: Global Anticancer Drugs Market Attractiveness Analysis, by Region, 2023-2031

    Figure 18: North America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 19: North America Anticancer Drugs Market Attractiveness Analysis, by Country, 2023–2031

    Figure 20: North America Anticancer Drugs Market Value Share Analysis, by Country, 2023 and 2031

    Figure 21: North America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

    Figure 22: North America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

    Figure 23: North America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

    Figure 24: North America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 25: North America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

    Figure 26:North America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

    Figure 27: Europe Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 28: Europe Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 29: Europe Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 30: Europe Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

    Figure 31: Europe Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

    Figure 32: Europe Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

    Figure 33: Europe Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 34: Europe Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

    Figure 35: Europe Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

    Figure 36: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 37: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 38: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 39: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

    Figure 40: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

    Figure 41: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

    Figure 42: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 43: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

    Figure 44: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

    Figure 45: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 46: Latin America Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 47: Latin America Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 48: Latin America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

    Figure 49: Latin America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

    Figure 50: Latin America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

    Figure 51: Latin America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 52: Latin America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

    Figure 53: Latin America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

    Figure 54: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 55: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 56: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 57: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

    Figure 58: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

    Figure 59: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

    Figure 60: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 61: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

    Figure 62: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved